Abstract
Amphethinile is a new spindle poison with a novel structure that has shown activity in the L1210, ADJ/PC6 and Walker carcinoma rodent tumours. In addition the agent appeared to have an improved therapeutic ratio compared to existing spindle poisons and is well absorbed when administered orally. The starting dose for the phase I study was 40 mg m-2 (1/10th mouse LD10) and further patients were studied at 200, 400, 800 and 1200 mg m-2, dose escalation being based on pharmacological monitoring. Significant toxic effects were seen only at 800 and 1200 mg m-2. At these doses patients experienced nausea and vomiting, light headedness during the infusion and varying degrees of lethargy following therapy. Two of six patients at 800 mg m-2 developed severe pain in the tumour bearing area 1-2 h after treatment and one experienced colicky abdominal pain. At 1200 mg m-2 two patients died within 48 h of treatment from what appeared to be vascular causes. Following these episodes the trial was discontinued. Neutropenia and alopecia occurred in two patients, one at 800 and one at 1200 mg m-2. These patients achieved the highest drug exposure in terms of area under the concentration x time curve. It was not possible to achieve an AUC consistently high enough to produce cytotoxic effects due to the occurrence of dose limiting toxicities thus amphethinile cannot at present be recommended for phase II testing by the i.v. route. The dose escalation scheme based on pharmacological monitoring resulted in a considerable saving in the duration of the trial. Further evaluation of this methodology is recommended.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Collins J. M., Zaharko D. S., Dedrick R. L., Chabner B. A. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep. 1986 Jan;70(1):73–80. [PubMed] [Google Scholar]
- Estey E., Hoth D., Simon R., Marsoni S., Leyland-Jones B., Wittes R. Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep. 1986 Sep;70(9):1105–1115. [PubMed] [Google Scholar]